Experience
Genzyme Corp.
CSRC et al.
International CSRC Investment Holdings Co., Ltd. (CSRC) and its subsidiaries granted Genzyme an exclusive license to several European and U.S. patents directed to treating Pompe Disease, a rare genetic disorder that is often fatal if untreated. Genzyme sells the only FDA-approved treatment for Pompe Disease and reports hundreds of millions in revenue annually from Genzyme’s market exclusivity and under CSRC’s license. Genzyme initiated arbitrations before the American Arbitration Association (AAA), arguing that its royalty obligations in Europe had ceased and its U.S. royalty obligations should end nearly two years before the expiration of the last licensed patent. CSRC also initiated a related litigation against Duke University for failing to assign to CSRC certain patents relating to the Pompe disease treatment research CSRC sponsored. CSRC reached a settlement agreement with Genzyme regarding the AAA arbitrations, with Genzyme agreeing to pay $180M as a compromise of the amount in dispute.
Genzyme Corp. v. CSRC et al., 01-19-0001-6937; 01-20-0000-5081, American Arbitration Association (AAA)
Finnegan revives key Jublia® patent at the Federal Circuit
Kaken Pharmaceutical Co., Ltd.; Bausch Health Care
Copyright victory on summary judgment and appeal for Dean Guitars and Estate of Pantera guitarist
Dean Guitars; Armadillo Enterprises, Inc.; Armadillo Distribution Enterprises, Inc.; Estate of Dimebag Darrell Abbott; Does 4-10; and Guitar Center, Inc.
Clean sweep at the PTAB for SharkNinja
SharkNinja Operating LLC et al
No confusion in trademark victory on summary judgment for the American Retirement Association
American Retirement Association
Federal Circuit upholds enhanced damages award to Finnegan client WCM Industries
WCM Industries, Inc.
Delta Faucet Company v. Globe Union Industrial Corp. et al.
Globe Union Industrial Corp.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Novartis Gene Therapies, Inc. et al.
Boston Scientific Corp. et al. v. Cook, Inc. et al.
Boston Scientific Corp. et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.